News for CorMedix Inc. (CRMD)

**media[555747]**

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a significant move by adding 412,087 shares of OptiNose Inc. (NASDAQ: OPTN) to its portfo

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) significantly increased its investment in InspireMD Inc. by acquiring an additional 7,419,918

This is our list of the best health care stocks based on the highest return over the last 30 days.

**media[520500]**

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ( CRMD), a biopharmaceutical company focused on developing and commercializing therape

Shares of CorMedix Inc. (CRMD) experienced a significant surge on Tuesday, jumping 32% to reach an intraday high of $10.89. This leap in stock price was triggered by the biopharmaceutical company's announcement of its preliminary, unaudited financial results for the fourth quarter and full year of 2024. CorMedix disclosed an…

”’ Q4 2024 Unaudited Net Revenue of Approximately $31mm ”’ ”’ FY 2024 Unaudited Net Revenue of Approximately $43mm ”’ ”’ Expects Q4 Adjusted EBITDA to Ex

CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

We recently published a list of Billionaire Paul Singer’s Top 12 Long-Term Stock Picks. In this article, we are going to take a look at where CorMedix Inc.

On November 12, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring 2,100,840 shares of Neuraxis Inc (NRXS). This transaction,

BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. ( CRMD), a biopharmaceutical company focused on developing and commercializing therape

Overview of Recent Transaction On October 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio), a prominent investment firm, executed a significant transaction

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss. Cormedix posted a loss of 17 cents per share for the third quarter, versus market expectations for a loss of 21 cents per share.

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of...

The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.55 A.M. EDT)..

Today's Daily Dose brings you news about the regulatory set back of Athenex's oral Paclitaxel and CorMedix's Defencath, ASLAN Pharma's Atopic Dermatitis trial results, FDA panel review of FibroGen's Roxadustat, Morphic Therapeutic's Phase 1 single ascending dose clinical trial of MORF-057, which is in development for the treatment of inflammatory bowel disease, and STRATA Skin's CEO transition.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.95%